STOCK TITAN
  1. Home
  2. News
  3. VSTM

Verastem Inc - VSTM STOCK NEWS

Welcome to our dedicated news page for Verastem (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verastem's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verastem's position in the market.

News
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
Rhea-AI Summary
Verastem Oncology (VSTM) to participate in fireside chat at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences
-
News
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Verastem Oncology (VSTM) Grants Stock Options to New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
-
News
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
Rhea-AI Summary
Verastem Oncology (Nasdaq: VSTM) plans to submit an Investigational New Drug (IND) for GFH375/VS-7375, an oral inhibitor targeting KRAS G12D, the most prevalent KRAS mutation in human cancer, in the first half of 2024. The potential best-in-class inhibitor is the lead program from Verastem's collaboration with GenFleet Therapeutics. The company aims to address the lack of FDA-approved therapies targeting KRAS G12D, which represents 26% of all KRAS mutations. The collaboration with GenFleet aims to advance three oncology discovery programs related to RAS pathway-driven cancers, with Verastem having the exclusive option to obtain a license to each of the three compounds after successful completion of pre-determined milestones in a Phase 1 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
News
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Rhea-AI Summary
Verastem Oncology (VSTM) initiates Phase 3 RAMP 301 trial to evaluate avutometinib and defactinib combination for recurrent low-grade serous ovarian cancer. The combination reports an objective response rate of 45% with manageable safety and tolerability profile. The company plans to submit an Accelerated Approval NDA based on mature data from RAMP 201 and FRAME trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.67%
Tags
clinical trial
-
News
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
Rhea-AI Summary
Let's Talk (LT) announces a new partnership with healthcare professionals and patients, aiming to enhance healthcare communication. The initiative focuses on improving patient-doctor dialogue and fostering better understanding of medical conditions and treatment options. This collaboration seeks to address the need for more effective communication in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Verastem Oncology (VSTM) reported plans to submit an application for accelerated approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024. They also presented additional patient subgroup data showing promising levels of response in LGSOC, regardless of prior therapies. The company entered into a collaboration with GenFleet Therapeutics and reported financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
earnings
News
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
Rhea-AI Summary
Verastem Oncology (Nasdaq: VSTM) announced the results of the first-ever LGSOC Patient Impact Survey, revealing the challenges faced by people living with low-grade serous ovarian cancer. The survey was developed through a global collaboration among patient advocacy groups and medical leaders to address the urgent needs of patients. LGSOC is a rare, highly recurrent ovarian cancer associated with slow but persistent tumor growth and a high mortality rate, relatively resistant to chemotherapy, with limited treatment options available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.65%
Tags
none
-
News
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
Rhea-AI Summary
Verastem Oncology announced results of a subgroup analysis of the Phase 2 RAMP 201 trial, showing the combination of avutometinib and defactinib demonstrated robust efficacy in recurrent low-grade serous ovarian cancer (LGSOC) regardless of prior therapies. The analysis revealed consistent objective response rates (ORRs) in patients who received 1-3 lines of therapy (45.5%) and ≥4 lines of therapy (44.4%). The combination yielded an ORR of 43.5% in patients who had poor response to their last prior treatment. Safety profiles were similar across subgroups, and adverse events were mostly mild to moderate. Verastem Oncology plans to file for accelerated approval with the FDA and initiate a Phase 3 confirmatory trial of avutometinib and defactinib in LGSOC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
News
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
Rhea-AI Summary
Verastem Oncology announces new executive leadership team appointments in preparation for potential commercial launch of avutometinib in combination with defactinib in low-grade serous ovarian cancer (LGSOC) and to support broader development program in RAS pathway-driven cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.85%
Tags
management
News
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Verastem Oncology grants stock options to new employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
Stock VSTM logo
Verastem Inc

Nasdaq:VSTM

VSTM Rankings

#3564 Ranked by Market Cap
#810 Ranked by Stock Gains
N/A Ranked by Dividends

VSTM Stock Data

285.84M
13.68M
0.55%
66.74%
2.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Needham

About VSTM

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com